Issues and progress with protein kinase inhibitors for cancer treatment
Top Cited Papers
- 1 April 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (4), 296-313
- https://doi.org/10.1038/nrd1066
Abstract
Identification of the key roles of protein kinases in cancer has led to extensive efforts to develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 such agents are now in clinical trials. Here, we consider the crucial issues in the development of kinase inhibitors for cancer, and discuss strategies to address the challenges raised by these issues in the light of preclinical and clinical experiences so far.Keywords
This publication has 85 references indexed in Scilit:
- Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CMLOncogene, 2002
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Management of malignant gastrointestinal stromal tumoursThe Lancet Oncology, 2002
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Mechanisms and Future Directions for Angiogenesis-Based Cancer TherapiesJournal of Clinical Oncology, 2002
- Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma ProtuberansJournal of Clinical Oncology, 2002
- Drug inhibition of angiogenesisCurrent Opinion in Pharmacology, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Scatter-factor and semaphorin receptors: cell signalling for invasive growthNature Reviews Cancer, 2002
- Oncogenic kinase signallingNature, 2001